Key Highlights

  • Net sales of USD 35.77 million missed the USD 62.00 million estimate, and loss per share was USD 0.31.
  • Net sales fell 19.4%, or USD 8.6 million, and Gross Profit fell 21.0% to USD 9.8 million.
  • Net loss narrowed to USD 6.4 million from USD 8.5 million, and general and administrative expense fell 15.6%.
  • Cash was USD 11.4 million, and the filing describes a Going Concern assessment and two consumer class actions.

PetMed Express (NASDAQ:PETS), an online pet pharmacy, reported fiscal second quarter 2027 net sales of USD 35.77 million, below the USD 62.00 million estimate. Loss per share was USD 0.31 against an estimated loss of USD 0.11 and USD 0.41 a year earlier. The quarter ended September 30, 2026.

Net sales fell about 19.4%, or USD 8.6 million, from the prior-year quarter. Net loss was USD 6.4 million against USD 8.5 million, and USD 12.6 million for the six months against USD 42.7 million.

Margins, Costs and Recurring Sales

Gross profit decreased about USD 2.6 million, or 21.0%, to USD 9.8 million from USD 12.4 million. General and administrative expenses decreased about USD 2.2 million, or 15.6%, to roughly USD 12.0 million from USD 14.2 million. Recurring net sales, which include AutoShip subscriptions and membership revenue, were 64.2% of total gross sales against 60.8% a year earlier.

Cash and Going Concern Assessment

Cash and cash equivalents were USD 11.4 million at September 30, 2026, against USD 21.4 million at March 31, 2026, and Working Capital was negative USD 17.0 million against negative USD 8.4 million. The filing states management's assessment identified conditions that raised substantial doubt about the company's ability to continue as a going concern, including declining cash, declining working capital and declining net sales. It also states management concluded that the doubt is alleviated by its plans, and the statements were prepared on a going concern basis.

Inventories fell to USD 6.3 million from USD 13.6 million at March 31, 2026, and total current Assets were USD 25.3 million against USD 43.6 million. Deferred Revenue for memberships was USD 0.6 million against USD 0.7 million. The filing also states that 1,536,840 shares issuable on vesting of restricted stock were excluded from the diluted per-share calculation for the quarter because they were antidilutive.

Legal Disclosure and Items to Follow

The filing describes two putative class actions concerning "regular" strikethrough pricing. One, filed April 18, 2024 in Allegheny County, Pennsylvania and removed to the Western District of Pennsylvania, alleges violations of Pennsylvania's Unfair Trade Practices and Consumer Protection Law and is stayed pending a motion in the other case. The other, filed February 14, 2025 in the Northern District of New York, alleges violations of New York and California consumer protection laws, and the company is moving to dismiss the second amended complaint. The filing states the company denies Liability and cannot determine materiality or estimate a range of potential liability. These matters are reported as stated and are flagged for human legal review.

The items to follow are net sales trends, cash use, working capital, management's plans and the outcome of the class actions.